Crispr Therapeutics price target raised to $66 from $57 at RBC Capital

RBC Capital analyst Luca Issi raised the firm’s price target on Crispr Therapeutics to $66 from $57 and keeps a Sector Perform rating on the shares after its “incremental” Q4 earnings update. With the “historic” approval of Casgevy in the U.S., E.U., Great Britain, Bahrain, and Saudi Arabia, the focus for the company remains on launch execution, the analyst tells investors in a research note. Phase I studies are ongoing for ANG3 and Lp(a), but while the firm “appreciates” all the progress, it also remains cautious on the launch and “struggles” to see upside following the recent move, RBC added.